Kalytera announced on
Data from Rodent Study are Strongly Positive
Results from this study were strongly positive, with the active moiety of R-107 demonstrating increased survival from 10% to 90% in septic mice over a week of follow-up. This extraordinary improvement in survival was reflected in the results of blood tests and microscopy showing full tissue protection in all the organs examined, including the liver, lung, and small intestine.
The study was conducted by Professor
R-107 is a Nitric Oxide Prodrug
R-107 is a liquid prodrug of nitric oxide that can be administered by injection, unlike nitric oxide gas, which requires a special type of delivery device, and complex administration by trained respiratory therapists. When administered by injection, R-107 is slowly hydrolyzed, releasing its active moiety, R-100, which in turn steadily and slowly releases nitric oxide into the lung tissue. This depot-like action of R-107 results in a sustained delivery of nitric oxide, allowing for a smooth delivery of the active drug over several days following a single dose of R-107.
Put simply, following injection, R-107 is metabolized, and releases R-100, which in turn releases nitric oxide into the tissues of the lung. R-100 is the payload of R-107.
The Potential of Nitric Oxide in Treatment of COVID-19 Associated Lung Disease
There are currently no approved treatments for lung disease caused by the COVID-19 virus, which is a severe form of lung failure called acute respiratory distress syndrome ('ARDS'). ARDS is the leading cause of death in COVID-19.
Nitric oxide is a gas that improves blood flow in areas of the lungs that are getting air, increasing the amount of oxygen in the blood stream.1
Along with being used to treat failing lungs, nitric oxide has also been found to have antiviral properties against coronaviruses.2
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 coronavirus) at this time.
Contact:
Tel: +1 888-861-2008
(C) 2020 Electronic News Publishing, source